Modulight Biotherapeutics is pioneering an optogenetic platform that enables cell-type and pathway-specific control of neuronal activity using proprietary light-sensitive proteins. Its lead asset, eOPN3, is a hypersensitive inhibitory opsin designed for clinical use and is initially being advanced for trigeminal pain, a severe and often drug-resistant facial pain disorder. Preclinical studies have also demonstrated promising efficacy in animal models of epilepsy and movement disorders such as Parkinson’s disease and essential tremor, underscoring the platform’s broader therapeutic potential. The company’s technology is licensed from YEDA, the commercial arm of the Weizmann Institute of Science, bolstering its scientific foundation. With the recently secured $12.2 million seed round, Modulight plans to complete IND-enabling studies, scale manufacturing, and begin FDA discussions for its first clinical program. The funding will also support expansion of its therapeutic pipeline and acceleration of additional preclinical programs. While still pre-revenue, the fresh capital positions the company to transition from discovery research toward initial human trials.

Total raised

$12M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2025